Ipsen, Genfit priority review for New Drug Application for liver disease thrapy

 

• New Drug Application granted priority review with PDUFA date set for June 10, 2024

• European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor

• Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade

https://finance.yahoo.com/news/ipsen-confirms-u-fda-grants-101500040.html